- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07569939
Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and/or Viral Tonsillitis (PharyTol)
3 augusti 2026 uppdaterad av: University Hospital, Clermont-Ferrand
The objective of this study is to conduct post-marketing clinical follow-up of four products: HMG, PHN, PHR, and TUR.
This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of sore throats related to acute pharyngitis and/or viral-origin tonsillitis, while also assessing the benefit/risk ratio of the products.
Studieöversikt
Status
Rekrytering
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
160
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Lise Laclautre
- Telefonnummer: +33473754963
- E-post: promo_interne_drci@chu-clermontferrand.fr
Studieorter
-
-
-
Clermont-Ferrand, Frankrike, 63003
- Rekrytering
- Chu Clermont Ferrand
-
Huvudutredare:
- Gisèle PICKERING
-
Kontakt:
- Lise Laclautre
- E-post: promo_interne_drci@chu-clermontferrand.fr
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Pharyngitis or tonsillitis or acute nasopharyngitis or viral-origin sore throat with odynophagia that began less than 72 hours before the inclusion visit according to the investigator's judgment
- Bacterial rhinopharyngitis with negative TROD test
- Effective contraception for female patients of childbearing age
- Cooperation and sufficient understanding to comply with the requirements of the trial
- Acceptance of registration in the SI-RIPH database
- Having received informed information and agreeing to give written consent
- Affiliated with the French Social Security scheme.
Exclusion Criteria:
- Hypersensitivity/previous allergy to any of the product components,
- Pharyngitis or tonsillitis or acute rhinopharyngitis complicated (phlegmon, acute otitis media, pneumonia…) or severely intolerable cough,
- Positive antigen test for influenza A/B or COVID-19 and infection requiring etiological treatment according to the recommendations,
- Other ongoing treatments for acute pharyngitis or tonsillitis (local treatment, antibiotics, corticosteroids, antiretroviral…),
- Comorbidities or health conditions deemed incompatible with the trial by the investigator,
- Recent otorhinolaryngology surgery (<6 months),
- Pulmonary pathology (Chronic Obstructive Pulmonary Disease, asthma…),
- Immunosuppression (according to patient's report),
- Pregnant or breastfeeding women,
- Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,
- Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HMG
Patients included in the "HMG" arm will receive the medical device of the same name.
|
Patients included in the "HMG" arm will receive the medical device of the same name.
|
|
Experimentell: PHN
Patients included in the "PHN" arm will receive the medical device of the same name.
|
Patients included in the "PHN" arm will receive the medical device of the same name.
|
|
Experimentell: PHR
Patients included in the "PHR" arm will receive the medical device of the same name.
|
Patients included in the "PHR" arm will receive the medical device of the same name.
|
|
Experimentell: TUR
Patients included in the "TUR" arm will receive the medical device of the same name.
|
Patients included in the "TUR" arm will receive the medical device of the same name.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Tolerance
Tidsram: From visit 1 (day 1) to visit 2 (day 8)
|
Collection of adverse events (AEs) during the period of use of HMG, PHN, PHR, TUR products in an electronic daily recording book
|
From visit 1 (day 1) to visit 2 (day 8)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Efficiency
Tidsram: From visit 1 (day 1) to the last day of use of the study product (day 8)
|
Clinical improvement (yes/no) defined as a decrease of at least 30% in the "total score for symptoms of sore throats" (STSMG) between baseline and the average of the scores measured during the last 3 days of use of the study product (days 5,6,7).
|
From visit 1 (day 1) to the last day of use of the study product (day 8)
|
|
Efficiency
Tidsram: From visite 1 (day 1) to visit 2 (day 8)
|
Clinical improvement (yes/no) at the medical examination: the assessment of pharyngeal erythema and general signs (lymphadenopathy, fever) by comparing the patient's data at inclusion and during the visit on day 8.
|
From visite 1 (day 1) to visit 2 (day 8)
|
|
Quality of life impact
Tidsram: From visite 1 (day 1) to visit 2 (day 8)
|
Change in quality of life measured by four questions before (Day 1) and after (Day 8) use of the study products concerning sleep, daily activities, fatigue, and irritability.
Each response will be rated between 0 (not impacted) and 10 (highly impacted) on a visual analog scale.
|
From visite 1 (day 1) to visit 2 (day 8)
|
|
Device defect
Tidsram: From visit A (day 1) to visit 2 (day 8)
|
Device defect assessed by recording any defect in terms of identity, quality, durability, reliability, safety, or performance, malfunction, or user error, or any defect in the information provided by the manufacturer in the electronic record book.
|
From visit A (day 1) to visit 2 (day 8)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
29 juli 2026
Primärt slutförande (Beräknad)
1 januari 2028
Avslutad studie (Beräknad)
1 januari 2028
Studieregistreringsdatum
Först inskickad
29 april 2026
Först inskickad som uppfyllde QC-kriterierna
29 april 2026
Första postat (Faktisk)
6 maj 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
5 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
3 augusti 2026
Senast verifierad
1 augusti 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RBHP 2026 PICKERING (PharyTol)
- 2026-A00430-51 (Annan identifierare: 2026-A00430-51)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .